All In Biotech

NDA 208054 · Blue Earth

Axumin

Fluciclovine F-18 · Intravenous · Radioactive Diagnostic Agent

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 21, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

May 27, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

48

7 Phase 3, 14 recruiting

FAERS reports

102

5 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 5, 2025.

Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Axumin is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment ( 1 ).

Mechanism: Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells. Fluciclovine F 18 is taken up to a greater extent in prostate cancer cells compared with surrounding normal tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AXUMIN · FLUCICLOVINE F-18 9-221mCi/ML · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluciclovine F-18" as an intervention, any sponsor and status, largest first.

All 48 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • positron emission tomogram abnormal22
  • no adverse event18
  • therapeutic response unexpected18
  • scan abnormal11
  • off label use8
  • false negative investigation result7
  • drug ineffective6
  • injection site extravasation5
  • false positive investigation result4
  • therapeutic product effect decreased4
  • diarrhoea3
  • extravasation2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
201814
201914
20201
20211
202230
20238
20244
202526
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Blue Earth

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.